285 related articles for article (PubMed ID: 28744562)
1. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats.
Kimura M; Oda Y; Hirose Y; Kimura H; Yoshino K; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Pharmacol Biochem Behav; 2021 Dec; 211():173288. PubMed ID: 34653399
[TBL] [Abstract][Full Text] [Related]
3. G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.
Oda Y; Tadokoro S; Takase M; Kanahara N; Watanabe H; Shirayama Y; Hashimoto K; Iyo M
J Psychopharmacol; 2015 Dec; 29(12):1308-13. PubMed ID: 26174132
[TBL] [Abstract][Full Text] [Related]
4. Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol.
Kimura M; Oda Y; Kimura H; Nangaku M; Hirose Y; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Pharmacol Biochem Behav; 2021 Mar; 202():173114. PubMed ID: 33485878
[TBL] [Abstract][Full Text] [Related]
5. Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.
Kimura M; Oda Y; Oishi K; Yoshino K; Kimura H; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Schizophr Res; 2021 Feb; 228():1-6. PubMed ID: 33429150
[TBL] [Abstract][Full Text] [Related]
6. GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis.
Kalkman HO; Loetscher E
J Neural Transm (Vienna); 2003 Jul; 110(7):803-12. PubMed ID: 12811640
[TBL] [Abstract][Full Text] [Related]
7. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
8. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
9. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
10. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function.
El Hage C; Bédard AM; Samaha AN
Neuropharmacology; 2015 Dec; 99():715-25. PubMed ID: 25823912
[TBL] [Abstract][Full Text] [Related]
12. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
de Bartolomeis A; Fiore G; Iasevoli F
Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
14. Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine.
Rupniak NM; Prestwich SA; Horton RW; Jenner P; Marsden CD
J Neural Transm; 1987; 68(1-2):113-25. PubMed ID: 3806083
[TBL] [Abstract][Full Text] [Related]
15. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
16. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
17. The role of striatal glutamatergic system in haloperidol-induced dopamine receptor supersensitivity and effects of monosialoganglioside GM1.
Schroeder H; Schroeder U; Sabel BA
Pharmacol Biochem Behav; 1997 Dec; 58(4):903-7. PubMed ID: 9408194
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment.
Servonnet A; Minogianis EA; Bouchard C; Bédard AM; Lévesque D; Rompré PP; Samaha AN
Neuropharmacology; 2017 Sep; 123():10-21. PubMed ID: 28522313
[TBL] [Abstract][Full Text] [Related]
19. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Bachus SE; Yang E; McCloskey SS; Minton JN
Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.
Yin J; Barr AM; Ramos-Miguel A; Procyshyn RM
Curr Neuropharmacol; 2017; 15(1):174-183. PubMed ID: 27264948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
